STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Reported on
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	P2
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	P2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	L2- 20 (P3)
Objectives	3	State specific objectives, including any prespecified hypotheses	L18 (P3) – L4 (P4)
Methods			
Study design	4	Present key elements of study design early in the paper	L9-13 (P4)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	L9-20 (P4)
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	L9-13 (P4)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	L16-20 (P4)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	L9-20 (P4)
Bias	9	Describe any efforts to address potential sources of bias	L16-17 (P4)
Study size	10	Explain how the study size was arrived at	L9-10 (P4)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	L17-20 (P4)
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	L4-6 (P5)
		(*b*) Describe any methods used to examine subgroups and interactions	L10-12 (P6)
		(*c*) Explain how missing data were addressed	N/A (no missing data)
		(*d*) If applicable, describe analytical methods taking account of sampling strategy	N/A (no analytical methods taking account of sampling strategy)
		(*e*) Describe any sensitivity analyses	N/A (no sensitivity analyses)
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	L10-16 (P5)
		(b) Give reasons for non-participation at each stage	N/A (no non-participation)

		(c) Consider use of a flow diagram	N/A (a flow diagram is not necessary in this study)
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1, 3
		(b) Indicate number of participants with missing data for each variable of interest	N/A (no missing data)
Outcome data	15*	Report numbers of outcome events or summary measures	Table 2
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A (because of small numbers)
		(*b*) Report category boundaries when continuous variables were categorized	N/A (no continuous variables)
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A (no relative risk was estimated)
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A (no other analyses)
Discussion			
Key results	18	Summarise key results with reference to study objectives	L3-6 (P7)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	L4-9 (P10)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	L9 (P7)-L4 (P9)
Generalisability	21	Discuss the generalisability (external validity) of the study results	L12-13 (P10)
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	L2-3(P11)

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: https://dx.doi.org/10.21037/tcr-21-2764
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version.